Clinical trial · Interventional
Use of Pyrvinium to Reverse Stomach Precancerous Conditions
Pyrvinium for Reversal of Precancerous Metaplasia and Dysplasia in the Stomach
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is carried out to find out if a drug called pyrvinium is able to convert pre-cancerous tissue in the stomach back to healthy tissue, to lower the chances of stomach cancer. Pyrvinium is a drug that has been used for a long time to treat pinworms in children and its anti-cancer properties are currently under investigation. Tests in animals have shown that pyrvinium made unhealthy tissue healthier and stopped some cells from growing in a bad way. Based on preclinical studies, the investigators hypothesise that the proportion of samples with pre-cancerous tissue in the stomach would decrease by 50% after exposure to pyrvinium at the 6-week timepoint, with anticipated durability of the response at the one-year follow-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| STOMACH NEOPLASM | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood biomarkers analyses | Procedure | — | UNRESOLVED |
| Gastric juice, saliva and stool collection and analyses | Other | — | UNRESOLVED |
| Oesophagogastroduodenoscopy (OGD) and biopsy | Procedure | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
| Pyrvinium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Pyrvinium
- description
- Pyrvinium will be administered to participants.
- interventionNames
- Drug: Pyrvinium
- Procedure: Blood biomarkers analyses
- Procedure: Oesophagogastroduodenoscopy (OGD) and biopsy
- Other: Gastric juice, saliva and stool collection and analyses
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo will be administered to participants.
- interventionNames
- Drug: Placebo
- Procedure: Blood biomarkers analyses
- Procedure: Oesophagogastroduodenoscopy (OGD) and biopsy
- Other: Gastric juice, saliva and stool collection and analyses
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * The subject is at least 21 years of age. * The subject has histologically proven extensive/marked intestinal metaplasia and/or dysplasia. * The subject is willing and able to provide signed and dated patient informed consent form indicating that he/she has been informed of all pertinent aspects of the study. Exclusion Criteria: * The subject has an active gastric cancer diagnosis. * The subject is pregnant. * The subject has a high-risk of bleeding complications due to anticoagulants or underlying medical condition such as bleeding disorders in whom biopsies are contraindicated. * The subject has impaired renal function. * The subject has impaired hepatic function. * The subject has fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency. * The subject has chronic bowel disease. * The subject has any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and in the judgement of the investigator would make the subject unsuitable for entry into the study. * The subject is unwilling or unable to provide signed informed consent.
References
Publications (0)
Data not yet available